Talphera (TLPH) Cash & Equivalents (2010 - 2026)
Talphera's (TLPH) quarterly Cash & Equivalents came in at $20.5 million in Q1 2026, up 281.31% year-on-year from $5.4 million in Q1 2025, and up 2.89% quarter-over-quarter from $20.0 million in Q4 2025.
Talphera (TLPH) Cash & Equivalents (2010 - 2026) Analysis & Trends
Talphera's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $20.5 million for Q1 2026.
- On a quarterly basis, Cash & Equivalents rose 281.31% year-over-year to $20.5 million in Q1 2026; TTM through Mar 2026 was $20.5 million, a 281.31% increase from a year earlier, with the FY2025 full-year figure at $20.0 million, up 125.28% from the prior year.
- Cash & Equivalents rose to $20.5 million in Q1 2026 per TLPH's latest filing, from $20.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $39.3 million in Q1 2022 and bottomed at $4.8 million in Q2 2023.
- The 5-year median for Cash & Equivalents is $12.7 million (2022), against an average of $14.4 million.
- Across the five-year window, Cash & Equivalents tumbled 71.01% in 2025 and soared 281.31% in 2026, its largest moves.
- Year by year, Cash & Equivalents stood at $15.3 million in 2022, then plunged by 38.59% to $9.4 million in 2023, then dropped by 5.52% to $8.9 million in 2024, then surged by 125.28% to $20.0 million in 2025, then climbed by 2.89% to $20.5 million in 2026.
- Per Business Quant, the three latest TLPH Cash & Equivalents figures stand at $20.5 million (Q1 2026), $20.0 million (Q4 2025), and $21.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | 20.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.55 Mn |
| Dec 31, 2025 | 19.97 Mn |
| Sep 30, 2025 | 21.03 Mn |
| Jun 30, 2025 | 6.18 Mn |
| Mar 31, 2025 | 5.39 Mn |
| Dec 31, 2024 | 8.86 Mn |
| Sep 30, 2024 | 11.12 Mn |
| Jun 30, 2024 | 13.42 Mn |
| Mar 31, 2024 | 18.58 Mn |
| Dec 31, 2023 | 9.38 Mn |
| Sep 30, 2023 | 11.73 Mn |
| Jun 30, 2023 | 4.77 Mn |
| Mar 31, 2023 | 11.64 Mn |
| Dec 31, 2022 | 15.28 Mn |
| Sep 30, 2022 | 12.73 Mn |
| Jun 30, 2022 | 15.17 Mn |
| Mar 31, 2022 | 39.30 Mn |
| Dec 31, 2021 | 51.63 Mn |
| Sep 30, 2021 | 8.27 Mn |
| Jun 30, 2021 | 21.33 Mn |